Haemonetics (NYSE: HAE) reported Q4 EPS of $0.90, $0.01 better than the analyst estimate of $0.89. Revenue for the quarter came in at $343.29 million versus the consensus estimate of $329.47 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.